en · de · es · fr · pt
sr9009-notes.peptides6088.com › Topic › Analytical Detection And Storage — Questions and Answers

Analytical Detection And Storage — Questions and Answers

By Editorial Desk · published 2025-11-22 · last reviewed 2026-01-11 · Topic

This is a working overview of reference standard, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-01-11 and is reviewed periodically as new material appears.

Analytical Detection and Storage

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Background and Mechanism

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

Sr9009 at a glance

PropertyValueNotes
Typical storage temperature-20 °C or lowerDesiccated and protected from light
Common analytical methodLC-MS/MSDetects parent drug and metabolites
Solubility classLipophilic; soluble in organic solventsLow aqueous solubility
Molecular weight437.94 g/molCalculated from reported formula
SynonymsSR9009; REV-ERB agonistCode name used in scientific literature

Analytical Detection and Stability

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Related pages on this site

Background and Research Status

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

Analytical and Handling Considerations

For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

SR9009 Background and Receptor Mechanism

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

Background from the literature

=== Toxicity === At present, the information needed to determine if HMX causes cancer is insufficient. Due to the lack of information, EPA has determined that HMX is not classifiable as to its human carcinogenicity. The available data on the effects on human health of exposure to HMX are limited. HMX causes CNS effects similar to those of RDX, but at considerably higher doses. In one study, volunteers submitted to patch testing, which produced skin irritation. Another study of a cohort of 93 workers at an ammunition plant found no hematological, hepatic, autoimmune, or renal diseases. However, the study did not quantify the levels of exposure to HMX. HMX exposure has been investigated in several studies on animals. Overall, the toxicity appears to be quite low. HMX is poorly absorbed by ingestion. When applied to the dermis, it induces mild skin irritation but not delayed contact sensitization. Various acute and subchronic neurobehavioral effects have been reported in rabbits and rodents, including ataxia, sedation, hyperkinesia, and convulsions. The chronic effects of HMX that have been documented through animal studies include decreased hemoglobin, increased serum alkaline phosphatase, and decreased albumin. Pathological changes were also observed in the animals' livers and kidneys. Gas exchange rate was used as an indicator of chemical stress in Northern bobwhite quail (Colinus virginianus) eggs, and no evidence of alterations in metabolic rates associated with HMX exposure was observed.

The most common molecule in the Universe, H2 (molecular hydrogen), is completely invisible to radio telescopes because it has no dipole; its electronic transitions are too energetic for optical telescopes, so detection of H2 required ultraviolet observations with a sounding rocket. Vibrational lines are often not specific to an individual molecule, allowing only the general class to be identified. For example, the vibrational lines of polycyclic aromatic hydrocarbons (PAHs) were identified in 1984, showing the class of molecules is very common in space, but it took until 2021 to identify any specific PAHs through their rotational lines.

Marvel Comics editor-in-chief Roy Thomas wanted to create a Canadian superhero and decided that wolverines were a typical Canadian animal that could inspire such a hero. He asked artist John Romita Sr. and writer Len Wein to devise a character of Canadian origin named Wolverine. Romita designed Wolverine's costume. Wolverine first appeared in the final "teaser" panel of The Incredible Hulk #180 (cover-dated October 1974), written by Wein and penciled by Herb Trimpe. The character then appeared in a number of advertisements in various Marvel Comics publications before making his first major appearance in The Incredible Hulk #181 (November 1974), again by the Wein–Trimpe team. In 2009, Trimpe said he "distinctly remembers" Romita's sketch and that, according to him, Romita and Wein "sewed the monster together [while he] shocked it to life". According to him, Wolverine was initially conceived as a minor character and there were no plans for his continuing popularity. Though sometimes credited as co-creator, Trimpe denied having had any role in Wolverine's creation. The character's introduction was ambiguous, revealing little beyond his being a superhuman agent of the Canadian government. He appears briefly in the following issue's conclusion to the story. Wolverine's next appearance was in Giant-Size X-Men (May 1975), written by Wein and penciled by Dave Cockrum, in which he is recruited for a new team of X-Men to rescue the original group. Gil Kane illustrated the cover artwork but drew Wolverine's mask with larger headpieces.

A small combination of these enhancer-bound transcription factors, when brought close to a promoter by a DNA loop, govern transcription level of the target gene. Mediator (a complex usually consisting of about 26 proteins in an interacting structure) communicates regulatory signals from enhancer DNA-bound transcription factors directly to the RNA polymerase II (pol II) enzyme bound to the promoter. Enhancers, when active, are generally transcribed from both strands of DNA with RNA polymerases acting in two different directions, producing two eRNAs as illustrated in the figure. An inactive enhancer may be bound by an inactive transcription factor. Phosphorylation of the transcription factor may activate it and that activated transcription factor may then activate the enhancer to which it is bound (see small red star representing phosphorylation of transcription factor bound to enhancer in the illustration). An activated enhancer begins transcription of its RNA before activating transcription of messenger RNA from its target gene.

With mutual arrangement with Leuven, he became professor in both universities from 1962, dividing his time between Leuven and New York. In 1974, the same year he received his Nobel Prize, he founded the ICP, which would later be renamed the de Duve Institute. He became emeritus professor of the University of Louvain in 1985, and of Rockefeller in 1988. De Duve was granted the rank of Viscount in 1989 by King Baudouin of Belgium. He was also a recipient of Francqui Prize, Gairdner Foundation International Award, Heineken Prize, and E.B. Wilson Medal. In 1974, he founded the International Institute of Cellular and Molecular Pathology in Brussels, eventually renamed the de Duve Institute in 2005. He was the founding President of the L'Oréal-UNESCO For Women in Science Awards. He died by legal euthanasia after long suffering from cancer and atrial fibrillation.

Sources: en.wikipedia.org

Reference notes

MNA Ali Pervaiz was appointed as a Minister of State with the allocated portfolios of Finance & Revenue, with an additional portfolio of the Power Division on 17 May. Foreign Minister Ishaq Dar was appointed Deputy Prime Minister of Pakistan through a notification from the Cabinet Division, this after the post had remained vacant for the past eleven years. Arifa Noor speculated in Dawn this was the result of Nawaz Sharif planning to reassert himself due to Ishaq Dar's "proximity" with Nawaz.

=== Lock and key hypothesis === This concept was suggested by the 19th-century chemist Emil Fischer. He proposed that the active site and substrate are two stable structures that fit perfectly without any further modification, just like a key fits into a lock. If one substrate perfectly binds to its active site, the interactions between them will be strongest, resulting in high catalytic efficiency. As time went by, limitations of this model started to appear. For example, the competitive enzyme inhibitor methylglucoside can bind tightly to the active site of 4-alpha-glucanotransferase and perfectly fits into it. However, 4-alpha-glucanotransferase is not active on methylglucoside and no glycosyl transfer occurs. The Lock and Key hypothesis cannot explain this, as it would predict a high efficiency of methylglucoside glycosyl transfer due to its tight binding. Apart from competitive inhibition, this theory cannot explain the mechanism of action of non-competitive inhibitors either, as they do not bind to the active site but nevertheless influence catalytic activity.

== Limitations == Chemotherapy does not always work, and even when it is useful, it may not completely destroy the cancer. People frequently fail to understand its limitations. In one study of people who had been newly diagnosed with incurable, stage 4 cancer, more than two-thirds of people with lung cancer and more than four-fifths of people with colorectal cancer still believed that chemotherapy was likely to cure their cancer. The blood–brain barrier poses an obstacle to delivery of chemotherapy to the brain. This is because the brain has an extensive system in place to protect it from harmful chemicals. Drug transporters can pump out drugs from the brain and brain's blood vessel cells into the cerebrospinal fluid and blood circulation. These transporters pump out most chemotherapy drugs, which reduces their efficacy for treatment of brain tumors. Only small lipophilic alkylating agents such as lomustine or temozolomide are able to cross this blood–brain barrier. Blood vessels in tumors are very different from those seen in normal tissues. As a tumor grows, tumor cells furthest away from the blood vessels become low in oxygen (hypoxic). To counteract this they then signal for new blood vessels to grow. The newly formed tumor vasculature is poorly formed and does not deliver an adequate blood supply to all areas of the tumor. This leads to issues with drug delivery because many drugs will be delivered to the tumor by the circulatory system.

== Theoretical Analysis of an Ideal Penning Trap == The motion of a single charged particle in an ideal Penning trap (with perfect alignment of its magnetic field to the quadrupole potential) is an exactly solvable system in both classical and quantum mechanics. The particle's motion along the trap's axis is simple harmonic motion, and the motion in the trap's xy-plane is a perturbation of cyclotron motion that reduces to cyclotron motion exactly in the zero-electric-field limit.

Sources: en.wikipedia.org

Reference notes

8 June Observation of the axial Higgs mode, a Higgs boson-like excitation in a charge density wave material, is reported. It was incorrectly reported in some press releases as a dark matter particle. Scientists provide an overview of the capabilities of missions and observatories for detecting various alien technosignatures. 9 June A study estimates the air pollution impacts on climate change and the ozone layer from rocket launches and re-entry of reusable components and debris in 2019 and from a theoretical future space industry extrapolated from the "billionaire space race". It concludes that substantial effects from routine space tourism should "motivate regulation". Researchers report a robotic finger covered in a type of manufactured living human skin. Researchers demonstrate an electronic skin giving biological skin-like haptic sensations and touch/pain-sensitivity to a robotic hand (1 June). A system of an electronic skin and a human-machine interface is reported that can enable remote sensed tactile perception, and wearable or robotic sensing of many hazardous substances and pathogens (1 June). A multilayer tactile sensor hydrogel-based robot skin is demonstrated (8 June). 10 June – The core of the globular cluster NGC 3201 is shown to harbor a sub-cluster of nearly a hundred black holes. The same study also confirms that the globular cluster NGC 6397 has ejected most of its original black hole population, and its inner mass excess is composed by hundreds of massive white dwarfs.

=== Electrochemical sensors === Electrochemical sensors can be used for label-free sensing of biomolecules. They detect changes and measure current between a probed metal electrode and an electrolyte containing the target analyte. A known potential to the electrode is then applied from a feedback current and the resulting current can be measured. For example, one technique using electrochemical sensing includes slowly raising the voltage causing chemical species at the electrode to be oxidized or reduced. Cell current vs voltage is plotted which can ultimately identify the quantity of chemical species consumed or produced at the electrode. Fluorescent tags can be used in conjunction with electrochemical sensors for ease of detection in a biological system.

West Berlin was under the sovereignty of the Western Allies and neither a Western German state nor part of one. However, it was in many ways integrated with West Germany under a special status. A new delimitation of the federal territory has been discussed since the Federal Republic was founded in 1949 and even before. Committees and expert commissions advocated a reduction of the number of states; academics (Werner Rutz, Meinhard Miegel, Adrian Ottnad, etc.) and politicians (Walter Döring, Hans Apel, and others) made proposals – some of them far-reaching – for redrawing boundaries but hardly anything came of these public discussions. Territorial reform is sometimes propagated by the richer states as a means to avoid or reduce fiscal transfers.

Specific vitamin A supplementation is particularly important for preventing further damage to the liver and skin. Ready-to-use therapeutic foods (RUTFs) and F-75 and F-100 milks were created to provide appropriate nutrition and caloric intake to those experiencing malnutrition. F-75 milk would be ideal when trying to reintroduce food into a malnourished person, and F-100 milk would be used to aid in weight gain. While RUTFs and F-100 milk were made to have the same nutritional value, RUTFs are beneficial as they are dehydrated and do not require much preparation. It is also important to note that infections are common in children with severe malnutrition and can further complicate treatment. Routine antibiotics, even in the absence of clinical infection, are generally given as a prophylactic measure, especially in regions with a high risk of infectious diseases. However, due to concerns about antibiotic resistance, there is debate over their routine use.

In the BATT trial, growth velocity was decreased, bone age advancement was slowed, aggressiveness was decreased, and masculinization, measured via Tanner staging of pubic hair and genitals, did not appear to further progress. However, the decrease in growth rate was modest and fell just short of reaching statistical significance (p = 0.053). Conversely, although the decrease in rate of bone maturation was described as modest similarly, the ratio of bone age to chronological age was significantly reduced (p < 0.0001). Linear growth and skeletal maturation during normal puberty is mainly due to estradiol and not testosterone in both boys and girls, and hence inhibition of these processes with the combination of bicalutamide and anastrozole in precocious puberty would in theory be mostly dependent on the aromatase inhibitor rather than on bicalutamide. Testicular volume increased mildly over the year that the boys were observed. A New Drug Application of bicalutamide for FMPP in the United States was submitted on the basis of the BATT trial data. However, the application was not approved by the Food and Drug Administration, which cited insufficient evidence of effectiveness. Although indication of bicalutamide for the use was not granted, the bicalutamide medication label was updated to include the findings of the study. In terms of side effects, the combination of bicalutamide and anastrozole in the study was described as well tolerated with no safety concerns. However, gynecomastia, attributed to bicalutamide, was observed in almost half of the boys.

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 measured?

Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.

How should SR9009 be stored?

Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.

What purity methods are used?

High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Network